loading
Xortx Therapeutics Inc stock is traded at $1.01, with a volume of 29,634. It is up +6.32% in the last 24 hours and up +13.87% over the past month. XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.95
Open:
$1.005
24h Volume:
29,634
Relative Volume:
0.25
Market Cap:
$3.26M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-101.00
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
+9.77%
1M Performance:
+13.87%
6M Performance:
-42.61%
1Y Performance:
-79.60%
1-Day Range:
Value
$0.95
$1.03
1-Week Range:
Value
$0.8721
$1.07
52-Week Range:
Value
$0.82
$4.98

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name
Name
Xortx Therapeutics Inc
Name
Phone
-
Name
Address
-
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
XRTX's Discussions on Twitter

Compare XRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XRTX
Xortx Therapeutics Inc
1.01 3.26M 0 -736.70K -4.14M -0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Xortx Therapeutics Inc Stock (XRTX) Latest News

pulisher
Mar 19, 2025

XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Announces Update for Discussion with the FDA - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan

Mar 19, 2025
pulisher
Feb 24, 2025

Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan

Feb 24, 2025
pulisher
Feb 15, 2025

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com

Feb 15, 2025
pulisher
Jan 29, 2025

XORTX to Present at Microcap Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan

Jan 29, 2025
pulisher
Jan 24, 2025

XORTX Therapeutics Announces Auditor Transition - MSN

Jan 24, 2025
pulisher
Jan 22, 2025

XORTX Announces Change of Auditor - TipRanks

Jan 22, 2025
pulisher
Jan 21, 2025

XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan

Jan 17, 2025
pulisher
Jan 16, 2025

XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel

Jan 16, 2025
pulisher
Jan 15, 2025

Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel

Jan 15, 2025
pulisher
Jan 06, 2025

XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan

Jan 06, 2025
pulisher
Dec 19, 2024

XORTX appoints finance veteran as its new CFO - MSN

Dec 19, 2024
pulisher
Dec 19, 2024

XORTX Therapeutics Welcomes New CFO Dr. Bumby - TipRanks

Dec 19, 2024
pulisher
Dec 19, 2024

XORTX Strengthens Executive Team - The Manila Times

Dec 19, 2024
pulisher
Dec 19, 2024

XORTX Therapeutics Taps Former Eli Lilly Veteran Dr. Michael Bumby as New CFO - StockTitan

Dec 19, 2024
pulisher
Dec 12, 2024

XORTX Therapeutics Unveils New Kidney Disease Discoveries - TipRanks

Dec 12, 2024
pulisher
Dec 12, 2024

XORTX Announces Presentation at the Rare and Genetic Disease Summit - GlobeNewswire

Dec 12, 2024
pulisher
Dec 12, 2024

XORTX Therapeutics Unveils Breakthrough ADPKD Research: Genetic Factors Key to Disease Progression - StockTitan

Dec 12, 2024
pulisher
Nov 15, 2024

XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Oct 24, 2024

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise

Oct 24, 2024
pulisher
Oct 24, 2024

XORTX Highlights Kidney Disease Study at ASN - TipRanks

Oct 24, 2024
pulisher
Oct 18, 2024

XORTX Secures $1.5 Million in Latest Offering - TipRanks

Oct 18, 2024
pulisher
Oct 18, 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Oct 18, 2024
pulisher
Oct 17, 2024

XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN

Oct 17, 2024
pulisher
Oct 17, 2024

XORTX Therapeutics Announces $1.5 Million Offering - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Oct 17, 2024

Xortx Therapeutics Inc Stock (XRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):